• Case-Based Roundtable
  • General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Chronic Spontaneous Urticaria
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

Article

Aldara gets FDA nod for treatment of sBCC

St. Paul, Minn. - Aldara (imiquimod) Cream 5 percent, a topical immune response modifier, has received U.S. Food and Drug Administration (FDA) approval for the treatment of superficial basal cell carcinoma (sBCC).

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Subscribe Now!
Related Videos
Related Content
Daily Derm Times: June 19, 2025
June 20th 2025

Daily Derm Times: June 19, 2025

Derm Dispatch: Advocating for Skin and Nail Health to Spread Melanoma Awareness
May 23rd 2025

Derm Dispatch: Advocating for Skin and Nail Health to Spread Melanoma Awareness

VALIANT Survey Shows High Rates of Depression in Patients with Vitiligo
June 19th 2025

VALIANT Survey Shows High Rates of Depression in Patients with Vitiligo

Derm Dispatch: Discussing Early Detection and Education With a Melanoma Survivor
May 20th 2025

Derm Dispatch: Discussing Early Detection and Education With a Melanoma Survivor

Ink to Impact: A Laser-Focused Mission in Justice and Dermatology
June 19th 2025

Ink to Impact: A Laser-Focused Mission in Justice and Dermatology

Daily Derm Times: June 18, 2025
June 19th 2025

Daily Derm Times: June 18, 2025

© 2025 MJH Life Sciences

All rights reserved.